EG BioMed specializes in developing innovative blood-based cancer diagnostics centered on DNA methylation technology. The company has been awarded multiple patents both in the U.S. and internationally, including recent patents for early detection of pancreatic cancer (US 12,258,636 B2) and breast cancer (US 12,203,140 B2). These advancements are supported by globally recognized quality certifications—CLIA Laboratory…

CHICAGO – April 28–29, 2025 – EG BioMed, a biotechnology company specializing in early cancer detection using methylated circulating cell-free DNA, today announced that it will present three scientific abstracts at the upcoming American Association for Cancer Research® (AACR) Annual Meeting 2025. These studies highlight the use of DNA methylation biomarkers for non-invasive cancer detection…

In the highly competitive U.S. precision medicine market, partnering with a reliable CLIA-certified laboratory is a key advantage for businesses seeking to rapidly enter the market. EG BioMed’s CLIA-certified laboratory partnership program offers a strategic solution to overcome market bottlenecks and quickly establish a foothold in the U.S. precision medicine sector. (SeeMore) Comprehensive Regulatory Compliance…